Santos Cristina Maria de Araújo Medeiros, Souza Amaxsell Thiago Barros de, Neta Antonia Pereira Rosa, Freire Liziane Virginia Pereira, Sarmento Ayane Cristine Alves, Medeiros Kleyton Santos de, Luchessi André Ducati, Cobucci Ricardo Ney, Gonçalves Ana Katherine, Crispim Janaina Cristiana de Oliveira
Postgraduate Program in Technological Development and Innovation in Medicines, Federal University of Rio Grande do Norte, Natal 59012-570, Brazil.
Postgraduate Program in Sciences Applied to Women's Health, Federal University of Rio Grande do Norte, Natal 59012-310, Brazil.
Int J Mol Sci. 2025 May 9;26(10):4564. doi: 10.3390/ijms26104564.
The clinical application of exosomal microRNAs as diagnostic biomarkers presents a promising approach for identifying potential markers of endometriosis. We conducted a systematic review of case-control studies to investigate exosomal microRNAs as epigenetic biomarkers potentially involved in the pathogenesis of endometriosis. A comprehensive literature search was performed across PubMed, Embase, Web of Science, and Scopus databases, yielding 702 studies, with 12 meeting the inclusion criteria after screening and full-text review. These studies included 191 women with confirmed endometriosis and 169 healthy controls. Quality assessment using the Newcastle-Ottawa Scale indicated a moderate quality across studies, with a common score of 5/9. In total, 668 exosomal microRNAs were found to be significantly differentially expressed between endometriosis patients and controls. In serum samples, 119 exosomal microRNAs were differentially expressed, with miR-22-3p, miR-320a, miR-320b, and miR-1273g-3p reported in more than one study. In endometrial tissue samples, miR-200c-3p and miR-425-5p were identified in more than one study, with miR-200c-3p consistently upregulated. Bioinformatic analysis indicated that these exosomal microRNAs are involved in key signaling pathways such as PI3K/Akt, MAPK, and TGF-β, which are associated with cell proliferation, migration, and inflammation. Despite these promising findings, variability in exosomal microRNA expression patterns across studies underscores the need for standardized methods and validation in large-scale, ethnically diverse cohorts. Future research should focus on rigorous validation studies to establish clinically relevant exosomal microRNAs for early diagnosis and improved patient outcomes.
外泌体微小RNA作为诊断生物标志物的临床应用为识别子宫内膜异位症的潜在标志物提供了一种有前景的方法。我们对病例对照研究进行了系统综述,以研究外泌体微小RNA作为可能参与子宫内膜异位症发病机制的表观遗传生物标志物。通过在PubMed、Embase、Web of Science和Scopus数据库中进行全面的文献检索,共获得702项研究,经筛选和全文审查后,有12项符合纳入标准。这些研究包括191例确诊为子宫内膜异位症的女性和169例健康对照。使用纽卡斯尔-渥太华量表进行的质量评估表明,各研究的质量中等,平均得分为5/9。总共发现668种外泌体微小RNA在子宫内膜异位症患者和对照之间存在显著差异表达。在血清样本中,有119种外泌体微小RNA差异表达,超过一项研究报道了miR-22-3p、miR-320a、miR-320b和miR-1273g-3p。在子宫内膜组织样本中,超过一项研究鉴定出了miR-200c-3p和miR-425-5p,其中miR-200c-3p持续上调。生物信息学分析表明,这些外泌体微小RNA参与了PI3K/Akt、MAPK和TGF-β等关键信号通路,这些通路与细胞增殖、迁移和炎症相关。尽管有这些有前景的发现,但各研究中外泌体微小RNA表达模式的变异性强调了在大规模、种族多样化队列中采用标准化方法和进行验证的必要性。未来的研究应侧重于严格的验证研究,以建立用于早期诊断和改善患者预后的临床相关外泌体微小RNA。